The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis

Singh-Franco, Devada; Pérez, Alexandra; Harrington, Catherine

doi:10.1111/j.1463-1326.2010.01337.x

Cited by 66 publications

(53 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, amylin remains effective at reducing food intake and body weight in the obese state (7). In fact, the amylin analog pramlintide is FDA approved for the treatment of diabetes but has the additional effect of reducing food intake and body weight in obese individuals (12,52,53). This finding, along with the ability of amylin receptor signaling to enhance the body weight-lowering effects of other neuroendocrine signals (22), has led to the notion that the amylin system is a strong candidate for future antiobesity drug development (30,47,51).…”

Section: Discussionmentioning

confidence: 99%

Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake

Mietlicki‐Baase

Olivos

Jeffrey

et al. 2015

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

Peripheral coadministration of amylin and leptin produces enhanced suppression of food intake and body weight, but the central nuclei mediating these effects remain unclear. Because each of these peptides controls feeding via actions at the ventral tegmental area (VTA), we tested the hypothesis that the VTA is a site of action for the cooperative effects of leptin and amylin on energy balance control. First, we show that intra-VTA injection of amylin and leptin at doses of each peptide that are effective in reducing food intake and body weight when administered separately produces an enhanced suppression of feeding when administered in combination. We also demonstrate that subthreshold doses of both amylin and leptin cause significant hypophagia and body weight loss when coadministered into the VTA. Additionally, we provide evidence that VTA amylin receptor blockade significantly attenuates the ability of intra-VTA leptin to reduce feeding and body weight gain. Together, these data provide the first evidence that the VTA mediates the interaction of amylin and leptin to cooperatively promote negative energy balance. obesity; mesolimbic; reward; islet amyloid polypeptide OBESITY REPRESENTS A PREVALENT, COSTLY HEALTH PROBLEM in the US and worldwide (11,43,44), yet effective noninvasive treatment options for this disease are extremely limited. Many pharmacotherapeutic strategies to date have attempted to treat obesity by targeting a single feeding-related neuroendocrine system, but the vast majority of these monotherapy approaches have failed to produce meaningful and sustained reductions in body weight (41). Therefore, attention has been turned to the notion that combination pharmacotherapies targeting more than one neuroendocrine feeding-relevant system may be more effective for the treatment of obesity (8,49,51).The pancreatic hormone amylin has been identified as a leading candidate for the development of combination pharmaceutical strategies for the treatment of obesity (47, 51). Amylin acts centrally to promote negative energy balance (24,50), and several reports have demonstrated that amylin can enhance the anorectic effects of other feeding-related signals in an additive if not synergistic manner (6,10,22,35). Of particular interest is that amylin interacts cooperatively with the adipose-derived hormone leptin to produce enhanced suppression of food intake and body weight (13,15). This amylinleptin interaction has been observed in rodents (13,42,48,56,57,59) and humans (46,48). Indeed, several studies demonstrate that peripheral administration of amylin and leptin (or agonists for their receptors) produces greater weight loss than either compound alone (48,56,59). Of critical importance for the treatment of obesity is the fact that although humans and rodent models exhibit reduced sensitivity to the energy balance effects of leptin in the obese state (1, 39), amylin appears to restore leptin sensitivity (13, 48, 56), thereby improving weight loss when amylin and leptin are coadministered.Although the body we...

show abstract

Section: Discussionmentioning

confidence: 99%

Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake

Mietlicki‐Baase

Olivos

Jeffrey

et al. 2015

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

show abstract

“…Notably, in the extension to 1 year, the placebo group regained their baseline weight but the pramlintide-induced weight loss was durable. Meta-analysis of randomized clinical trials in obese patients supports a mild but statistically significant weight loss of just over 2 kg with pramlintide compared with placebo [80].…”

Section: Accepted Manuscriptmentioning

confidence: 99%

Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents

Samson

Garber

2016

Best Practice & Research Clinical Endocrinology & Metab

View full text Add to dashboard Cite

“…Numerous studies have been performed on obese patients with PCOS, who received metformin. While the irst studies seemed to demonstrate its efects in terms of weight loss, decreased serum androgen levels (and implicitly hirsutism), restoration of menstrual cycles, and induction of ovulation [54], further studies concluded its inefectiveness in treating hirsutism or increasing live birth rates, even if it is efective in increasing the ovulatory rates and pregnancy rates. Metformin is no longer used as a irst-line treatment for oligomenorrhea or weight loss.…”

Section: Diabetes Drugsmentioning

confidence: 99%

Lifestyle Changes and Weight Loss: Effects in PCOS

Ionescu¹,

Popescu²,

Banacu³

et al. 2018

Debatable Topics in PCOS Patients

View full text Add to dashboard Cite

Even though controversies surrounding the polycystic ovary syndrome are not yet close to be solved, its clinical manifestations are well known-insulin resistance and obesity, hirsutism, irregular and anovulatory menstrual cycles. The treatment of polycystic ovarian syndrome (PCOS) is mainly symptomatic as its etiology is not yet clear. Lifestyle changes are the primary therapy in overweight and obese women with PCOS. According to majority of the studies, lifestyle changes are the most efective form of treatment not only for weight loss but also for the improvement of insulin sensitivity, decreasing incidence of metabolic syndrome and type 2 diabetes. Studies also show that weight loss has fertility beneits by restoring ovulatory cycles. Although initial studies researching pharmacologic treatment were showing excellent results concerning the weight loss, maintenance of weight loss and reduction of cardiovascular risks, some of these drugs were in the end, has proven to actually increase the risk for cardiovascular events and were removed from the market. Bariatric surgery has been demonstrated to improve or even cure type 2 diabetes, hypertension, hyperlipidemia, and obstructive sleep apnea. More so, there are studies that reported complete resolution of all features of PCOS, even hirsutism, hyperandrogenism, anovulation, and menstrual irregularity.

show abstract

The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis

Cited by 66 publications

References 25 publications

Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake

Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake

Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents

Lifestyle Changes and Weight Loss: Effects in PCOS

Contact Info

Product

Resources

About